NEO-212 is under clinical development by Neonc Technologies and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NEO-212’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NEO-212 overview
NEO-212 is under development for the treatment of astrocytoma, glioblastoma, uncontrolled brain metastasis in patients with select solid tumors, nasopharyngeal carcinoma, melanoma and metastatic breast cancer. The drug candidate is administered through the intranasal and oral route. NEO-212 is a new chemical entity. The drug candidate constitutes alkylating agent temozolomide conjugated to perillyl alcohol. It acts by targeting DNA strands of cancer cells.
Neonc Technologies overview
Neonc Technologies (NTI) is an early-stage cancer biotechnology company that focuses on the development of intranasal inhalation and other non-invasive therapies for the treatment of malignant brain cancer, lung cancer and other brain cancers. The company’s product portfolio includes NEO100, a purified form of the natural compound perillyl alcohol (POH); NEO102, an isoform of the natural compound POH; NEO104, is a variant of the natural compound perillyl alcohol; and NEO212 is the chemical conjugation of DNA alkylating agent temozolomide (TMZ) to POH. Rolipram-POH (NEO214), Valproic acid-POH (NEO216), 3-bromopyruvate POH (NEO218), Dopamine POH (NEO312), NEO400 (TMZ POH Linoleic Acid) and NEO412 is for actinic keratosis and skin melanomas. It works in partnership with active pharmaceutical ingredients manufacturer to develop and produce proprietary monoterpenes. The company also conducts clinical trials for its products. NTI is headquartered in Los Angeles, California, the US.
For a complete picture of NEO-212’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
